NCT05238337View on ClinicalTrials.gov

A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

March 24, 2022

Study Completion Date

March 24, 2022

Conditions
Absorption, Metabolism and Excretion in Healthy Volunteers
Interventions
DRUG

[14C]-PBI-200

\[14C\]-radio-labeled-PBI-200

Trial Locations (1)

53704

Labcorp Clinical Research Unit Inc, Madison

Sponsors
All Listed Sponsors
lead

Pyramid Biosciences

INDUSTRY